Pediatric patients that received mTOR inhibitor therapy were more likely to experience mouth ulceration, stomatitis, convulsion, acneiform rash, arthralgias, diarrhea, thrombocytopenia, hyperlipidemia and lipoproteinemia than those treated with non-mTOR inhibitor therapy. This evidence concerns the gene MTOR and Thrombocytopenia.